Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: First Quarter 2011 Operating Results and Corporate Update
04 mai 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, May 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that it...
Arbutus Biopharma Logo
Tekmira and the National Cancer Institute Publish Promising Data Demonstrating the Anti-Tumor Activity of a Novel Cancer Target
21 avr. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 21, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira Announces USPTO Issuance of Key Patents Covering LNP Manufacturing Process and Mitigation of siRNA Immune Stimulation
12 avr. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 12, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira Comments on Answer and Counterclaim Filed by Alnylam Pharmaceuticals
07 avr. 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, B.C., April 7, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, reports that Alnylam...
Arbutus Biopharma Logo
Tekmira and Collaborators Present Data at the American Association for Cancer Research (AACR) Meeting on Tekmira's Lead Oncology Product, TKM-PLK1, and an Oncology Product Candidate Targeting Kinase WEE1
04 avr. 2011 16h35 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 4, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Reports 2010 Audited Results
30 mars 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2010 Audited Results
28 mars 2011 08h00 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information
16 mars 2011 16h40 HE | Arbutus Biopharma Corporation
Complaint Also Alleges Unfair and Deceptive Trade Practices, Unjust Enrichment, Unfair Competition and False Advertising about Tekmira's Proprietary Lipid Nanoparticle (LNP) Technology Conference...
Arbutus Biopharma Logo
Tekmira Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
10 mars 2011 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Proof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology
10 janv. 2011 08h30 HE | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...